Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

January 31, 2010

Study Completion Date

September 30, 2011

Conditions
Peritoneal Cavity Cancer
Interventions
DRUG

fluorouracil

Post-operative day 1 and day 2, 600mg/m\^2 intraperitoneal (IP) held for 23 hours

DRUG

leucovorin calcium

Day 0 200 mg/m\^2 intraperitoneal held for 2 hours

DRUG

oxaliplatin

Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m\^2

PROCEDURE

cytoreductive surgery

Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT00625092 - Hyperthermic Intraperitoneal Oxaliplatin for Peritoneal Malignancies | Biotech Hunter | Biotech Hunter